Matthew James Armstrong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew James Armstrong has a total of 505 co-authors. Here are the top co-authors by number of shared publications:
- Philip Noel Newsome
King’s College London and King’s College Hospital, London, UK
22 shared publications - Jeremy W. Tomlinson
Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK
17 shared publications - Richard Parker
Leeds Liver Unit St James's University Hospital Leeds UK
15 shared publications Diarmaid D. Houlihan
National Liver Unit, St. Vincent's University Hospital, Dublin, Ireland
10 shared publications- Ian Ac Rowe
Leeds Institute for Medical Research, University of Leeds, Leeds, UK
10 shared publications - Felicity Rhian Williams
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
7 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
Standardised assessment of liver from donors with haemochromatosis
Cristine Brooke Pathirannehalage Don, Elijah Ablorsu, Matthew Armstrong, Owen Cain, Bobby V.M. Dasari. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.26.0011
- 10 September 2026
- Published by Korean Liver Transplantation Society in Annals of Liver Transplantation
Open AccessStandardised assessment of liver from donors with haemochromatosis
Cristine Brooke Pathirannehalage Don, Elijah Ablorsu, Matthew Armstrong, Owen Cain, Bobby V.M. Dasari. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.26.0011
- Top Cited PapersOpen Access
- 23 May 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (6)
Skeletal muscle and MASLD: Mechanistic and clinical insights
Metabolic dysfunction–associated steatotic liver disease (MASLD) is intrinsically linked with widespread metabolic perturbations, including within skeletal muscle. Indeed, MASLD is associated with a range of skeletal muscle abnormalities, including insulin resistance, myosteatosis, and sarcopenia, which all converge on the liver to drive disease progression and adverse patient outcomes. This review explores the mechanistic links between skeletal muscle and MASLD, including the role of abnormal glycemic control, systemic inflammation, and disordered myokine signaling. In turn, we discuss how intrinsic liver pathology can feed back to further exacerbate poor skeletal muscle health. Given the central importance of skeletal muscle in MASLD pathogenesis, it offers clinicians an opportunity to intervene for therapeutic benefit. We, therefore, summarize the role of nutrition and physical activity on skeletal muscle mass, quality, and metabolic function and discuss the knock-on effect this has on the liver. An awareness of these treatment strategies is particularly important in the era of effective pharmacological and surgical weight loss interventions, which can be associated with the development of sarcopenia. Finally, we highlight a number of promising drug agents in the clinical trial pipeline that specifically target skeletal muscle in an attempt to improve metabolic and physical functioning.
- 23 May 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (6)
Top Cited PapersOpen AccessSkeletal muscle and MASLD: Mechanistic and clinical insights
Metabolic dysfunction–associated steatotic liver disease (MASLD) is intrinsically linked with widespread metabolic perturbations, including within skeletal muscle. Indeed, MASLD is associated with a range of skeletal muscle abnormalities, including insulin resistance, myosteatosis, and sarcopenia, which all converge on the liver to drive disease progression and adverse patient outcomes. This review explores the mechanistic links between skeletal muscle and MASLD, including the role of abnormal glycemic control, systemic inflammation, and disordered myokine signaling. In turn, we discuss how intrinsic liver pathology can feed back to further exacerbate poor skeletal muscle health. Given the central importance of skeletal muscle in MASLD pathogenesis, it offers clinicians an opportunity to intervene for therapeutic benefit. We, therefore, summarize the role of nutrition and physical activity on skeletal muscle mass, quality, and metabolic function and discuss the knock-on effect this has on the liver. An awareness of these treatment strategies is particularly important in the era of effective pharmacological and surgical weight loss interventions, which can be associated with the development of sarcopenia. Finally, we highlight a number of promising drug agents in the clinical trial pipeline that specifically target skeletal muscle in an attempt to improve metabolic and physical functioning.
- 20 May 2025
- Published by BMJ in Frontline Gastroenterology
Multidisciplinary approach to malnutrition and physical frailty in patients with decompensated cirrhosis
Malnutrition and physical frailty are major complications of decompensated cirrhosis. They are associated with significant morbidity (ie, unplanned hospitalisation, critical care unit utilisation, infections) and a two-fold increase in mortality. It is, therefore, essential to identify patients at risk and initiate specific nutritional, lifestyle, exercise and mental health interventions to stabilise and/or ideally reverse the negative effects of physical frailty. This overview aims to summarise the clinical tools available to assess nutritional status and physical frailty, together with the benefits and future challenges of a multidisciplinary team approach to optimise muscle health and physical fitness in patients with decompensated cirrhosis.
- 20 May 2025
- Published by BMJ in Frontline Gastroenterology
Multidisciplinary approach to malnutrition and physical frailty in patients with decompensated cirrhosis
Malnutrition and physical frailty are major complications of decompensated cirrhosis. They are associated with significant morbidity (ie, unplanned hospitalisation, critical care unit utilisation, infections) and a two-fold increase in mortality. It is, therefore, essential to identify patients at risk and initiate specific nutritional, lifestyle, exercise and mental health interventions to stabilise and/or ideally reverse the negative effects of physical frailty. This overview aims to summarise the clinical tools available to assess nutritional status and physical frailty, together with the benefits and future challenges of a multidisciplinary team approach to optimise muscle health and physical fitness in patients with decompensated cirrhosis.
- Open Access
- 19 May 2025
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 14, e09
The Management of Obesity Before Catheter Ablation of AF: The Missing Piece?
Obesity independently increases AF risk and negatively affects the outcomes of catheter ablation. This review examines the relationship between obesity and AF, focusing on structural and electrical remodelling. Multiple studies demonstrate worse ablation outcomes in patients with obesity. Pre-ablation weight loss improves outcomes and maintaining weight loss post-ablation is equally important. Risk factor modification programmes show promise, however they require a large investment in resources. Less intensive strategies focusing on diet and exercise have shown mixed results. Glucagon-like peptide-1 receptor agonists have been identified as potential adjunct therapies. They have multiple effects, including preferential reduction of epicardial adipose tissue and an anti-inflammatory action. Further research is needed to establish their efficacy in improving ablation outcomes. This review highlights the importance of weight management in AF treatment and suggests potential monitoring strategies using cardiac imaging. Future studies may shift the paradigm for the management of AF patients with obesity who are undergoing ablation.
- 19 May 2025
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 14, e09
Open AccessThe Management of Obesity Before Catheter Ablation of AF: The Missing Piece?
Obesity independently increases AF risk and negatively affects the outcomes of catheter ablation. This review examines the relationship between obesity and AF, focusing on structural and electrical remodelling. Multiple studies demonstrate worse ablation outcomes in patients with obesity. Pre-ablation weight loss improves outcomes and maintaining weight loss post-ablation is equally important. Risk factor modification programmes show promise, however they require a large investment in resources. Less intensive strategies focusing on diet and exercise have shown mixed results. Glucagon-like peptide-1 receptor agonists have been identified as potential adjunct therapies. They have multiple effects, including preferential reduction of epicardial adipose tissue and an anti-inflammatory action. Further research is needed to establish their efficacy in improving ablation outcomes. This review highlights the importance of weight management in AF treatment and suggests potential monitoring strategies using cardiac imaging. Future studies may shift the paradigm for the management of AF patients with obesity who are undergoing ablation.
- Open Access
- 28 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 710-718
Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
Aims: Weight loss mediated by glucagon‐like peptide‐1 (GLP‐1) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD) and associated steatohepatitis (MASH). We evaluated weight changes in adults with MASLD/MASH with or without type 2 diabetes receiving the GLP‐1 analogue semaglutide. Materials and Methods: This was a post hoc analysis of data from three 48–72‐week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy‐confirmed MASH (NCT02970942 and NCT03987451). Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [ n = 163]) and placebo ( n = 137) were analysed at 1 year. Weight changes were analysed by type 2 diabetes status (type 2 diabetes [ n = 209], pre‐type 2 diabetes [ n = 51] and no diabetes [ n = 40]) and by other cardiometabolic risk parameters using analysis of covariance and Spearman's rank correlations. Results: The overall mean weight change was −11.1 kg (−11.7%) and −0.7 kg (−0.6%) with semaglutide and placebo, respectively. While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (−10.2 kg; −10.8%), pre‐type 2 diabetes (−9.8 kg; −10.2%) and no diabetes (−11.6 kg; −13.1%). Differences between groups were not statistically significant ( p > 0.50 for all). Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change. Conclusions: People with MASLD/MASH had similar semaglutide‐mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.
- 28 November 2024
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (2) , 710-718
Open AccessSimilar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
Aims: Weight loss mediated by glucagon‐like peptide‐1 (GLP‐1) analogues is lower in patients with type 2 diabetes versus those without. Type 2 diabetes and obesity are risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD) and associated steatohepatitis (MASH). We evaluated weight changes in adults with MASLD/MASH with or without type 2 diabetes receiving the GLP‐1 analogue semaglutide. Materials and Methods: This was a post hoc analysis of data from three 48–72‐week randomised trials investigating the effect of semaglutide versus placebo in adults with MASLD (NCT03357380) or biopsy‐confirmed MASH (NCT02970942 and NCT03987451). Pooled data for semaglutide (0.4 mg once daily and 2.4 mg once weekly [ n = 163]) and placebo ( n = 137) were analysed at 1 year. Weight changes were analysed by type 2 diabetes status (type 2 diabetes [ n = 209], pre‐type 2 diabetes [ n = 51] and no diabetes [ n = 40]) and by other cardiometabolic risk parameters using analysis of covariance and Spearman's rank correlations. Results: The overall mean weight change was −11.1 kg (−11.7%) and −0.7 kg (−0.6%) with semaglutide and placebo, respectively. While numerically higher for people without type 2 diabetes, estimated treatment differences with semaglutide versus placebo were similar overall for people with type 2 diabetes (−10.2 kg; −10.8%), pre‐type 2 diabetes (−9.8 kg; −10.2%) and no diabetes (−11.6 kg; −13.1%). Differences between groups were not statistically significant ( p > 0.50 for all). Baseline fasting plasma glucose, glycated haemoglobin, insulin levels, insulin resistance and lipids did not correlate with weight change. Conclusions: People with MASLD/MASH had similar semaglutide‐mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.
- Open Access
- 3 January 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (4) , 547-557
Duke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
Summary: Background: There remains a lack of consensus on how to assess functional exercise capacity and physical frailty in patients with advanced chronic liver disease (CLD) being assessed for liver transplantation (LT). Aim To investigate prospectively the utility of the Duke Activity Status Index (DASI) and Liver Frailty Index (LFI) in ambulatory patients with CLD.Aim: To investigate prospectively the utility of the Duke Activity Status Index (DASI) and Liver Frailty Index (LFI) in ambulatory patients with CLD.Methods: We recruited patients from outpatient clinics at University Hospitals Birmingham, UK (2018–2019). We prospectively collated the DASI and LFI to identify the prevalence of, respectively, functional capacity and physical frailty, and to evaluate their accuracy in predicting overall and pre‐LT mortality.Results: We studied 307 patients (57% male; median age 54 years; UKELD 52). Median DASI score was 28.7 (IQR 16.2–50.2), mean LFI was 3.82 (SD = 0.72), and 81% were defined either ‘pre‐frail’ or ‘frail’. Female sex and hyponatraemia were significant independent predictors of both DASI and LFI. Age and encephalopathy were significant independent predictors of LFI, while BMI significantly predicted DASI. DASI and LFI were significantly related to overall (HR 0.97, p = 0.001 [DASI], HR 2.04, p = 0.001 [LFI]) and pre‐LT mortality (HR 0.96, p = 0.02 [DASI], HR 1.94, p = 0.04 [LFI]).Conclusions: Poor functional exercise capacity and physical frailty are highly prevalent among ambulatory patients with CLD who are being assessed for LT. The DASI and LFI are simple, low‐cost tools that predict overall and pre‐LT mortality. Implementation of both should be considered in all outpatients with CLD to highlight those who may benefit from targeted nutritional and exercise interventions.
- 3 January 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (4) , 547-557
Open AccessDuke Activity Status Index and Liver Frailty Index predict mortality in ambulatory patients with advanced chronic liver disease: A prospective, observational study
Summary: Background: There remains a lack of consensus on how to assess functional exercise capacity and physical frailty in patients with advanced chronic liver disease (CLD) being assessed for liver transplantation (LT). Aim To investigate prospectively the utility of the Duke Activity Status Index (DASI) and Liver Frailty Index (LFI) in ambulatory patients with CLD.Aim: To investigate prospectively the utility of the Duke Activity Status Index (DASI) and Liver Frailty Index (LFI) in ambulatory patients with CLD.Methods: We recruited patients from outpatient clinics at University Hospitals Birmingham, UK (2018–2019). We prospectively collated the DASI and LFI to identify the prevalence of, respectively, functional capacity and physical frailty, and to evaluate their accuracy in predicting overall and pre‐LT mortality.Results: We studied 307 patients (57% male; median age 54 years; UKELD 52). Median DASI score was 28.7 (IQR 16.2–50.2), mean LFI was 3.82 (SD = 0.72), and 81% were defined either ‘pre‐frail’ or ‘frail’. Female sex and hyponatraemia were significant independent predictors of both DASI and LFI. Age and encephalopathy were significant independent predictors of LFI, while BMI significantly predicted DASI. DASI and LFI were significantly related to overall (HR 0.97, p = 0.001 [DASI], HR 2.04, p = 0.001 [LFI]) and pre‐LT mortality (HR 0.96, p = 0.02 [DASI], HR 1.94, p = 0.04 [LFI]).Conclusions: Poor functional exercise capacity and physical frailty are highly prevalent among ambulatory patients with CLD who are being assessed for LT. The DASI and LFI are simple, low‐cost tools that predict overall and pre‐LT mortality. Implementation of both should be considered in all outpatients with CLD to highlight those who may benefit from targeted nutritional and exercise interventions.
- 27 July 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (4) , 484-485
Editorial: Feeling better about NASH—Authors' reply
LINKED CONTENT: This article is linked to Romero Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.17598 and https://doi.org/10.1111/apt.17621
- 27 July 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (4) , 484-485
Editorial: Feeling better about NASH—Authors' reply
LINKED CONTENT: This article is linked to Romero Gomez et al papers. To view these articles, visit https://doi.org/10.1111/apt.17598 and https://doi.org/10.1111/apt.17621
- Open Access
- 16 June 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (4) , 395-403
Improved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial
Summary: Background: Non‐alcoholic steatohepatitis (NASH) can adversely affect health‐related quality of life (HRQoL).Aims: This double‐blind, placebo‐controlled, phase 2 trial aimed to report the effects of the glucagon‐like peptide‐1 receptor agonist, semaglutide, on HRQoL in patients with NASH as a secondary endpoint.Methods: Adults with biopsy‐proven NASH and stage 1–3 fibrosis were randomised (3:3:3:1:1:1) to once‐daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks. Patients were invited to complete the Short Form‐36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.Results: Between January 2017 and September 2018, 320 patients were enrolled. At 72 weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96–6.55; p = 0.0003); bodily pain (ETD 5.07; 95% CI: 2.15–7.99; p = 0.0007); physical functioning (ETD 3.51; 95% CI: 1.16–5.86; p = 0.0034); role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28–5.33; p = 0.0294); social functioning (ETD 3.16; 95% CI: 0.53–5.78; p = 0.0183) and vitality (ETD 4.47; 95% CI: 1.63–7.32; p = 0.0021). There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: −1.59 to 3.62; p = 0.4441). After 72 weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (p = 0.014).Conclusions: Treatment with semaglutide is associated with improvements in the physical components of HRQoL in patients with biopsy‐proven NASH and fibrosis compared with placebo. ClinicalTrials.gov: NCT02970942.
- 16 June 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (4) , 395-403
Open AccessImproved health‐related quality of life with semaglutide in people with non‐alcoholic steatohepatitis: A randomised trial
Summary: Background: Non‐alcoholic steatohepatitis (NASH) can adversely affect health‐related quality of life (HRQoL).Aims: This double‐blind, placebo‐controlled, phase 2 trial aimed to report the effects of the glucagon‐like peptide‐1 receptor agonist, semaglutide, on HRQoL in patients with NASH as a secondary endpoint.Methods: Adults with biopsy‐proven NASH and stage 1–3 fibrosis were randomised (3:3:3:1:1:1) to once‐daily subcutaneous semaglutide 0.1, 0.2 or 0.4 mg, or placebo, for 72 weeks. Patients were invited to complete the Short Form‐36 version 2.0 questionnaire at weeks 0, 28, 52 and 72.Results: Between January 2017 and September 2018, 320 patients were enrolled. At 72 weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96–6.55; p = 0.0003); bodily pain (ETD 5.07; 95% CI: 2.15–7.99; p = 0.0007); physical functioning (ETD 3.51; 95% CI: 1.16–5.86; p = 0.0034); role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28–5.33; p = 0.0294); social functioning (ETD 3.16; 95% CI: 0.53–5.78; p = 0.0183) and vitality (ETD 4.47; 95% CI: 1.63–7.32; p = 0.0021). There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: −1.59 to 3.62; p = 0.4441). After 72 weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (p = 0.014).Conclusions: Treatment with semaglutide is associated with improvements in the physical components of HRQoL in patients with biopsy‐proven NASH and fibrosis compared with placebo. ClinicalTrials.gov: NCT02970942.